Unichem Laboratories Share Price
Sector: Major Drugs
You have to be logged in to add this to Watchlist.
Login or Register
725.90 -2.60 (-0.36%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
711.05
Today’s High
744.9
52 Week Low
398.7
52 Week High
755.15
732.10 +5.00 (0.69%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
704.1
Today’s High
745
52 Week Low
399
52 Week High
754.2
Key Metrics
- Market Cap (In Cr) 5119.2
- Beta 0.27
- Div. Yield (%) 0
- P/B 2.17
- TTM P/E -
- Sector P/E 32.9
- D/E -
- Open Price 727.6
- Prev Close 728.5
Unichem Laboratories Analysis
Price Analysis
-
1 Week13.54%
-
3 Months37.4%
-
6 Month29.67%
-
YTD79.13%
-
1 Year72.01%
Risk Meter
- 36% Low risk
- 36% Moderate risk
- 36% Balanced Risk
- 36% High risk
- 36% Extreme risk
Unichem Laboratories News
Unichem Laboratories Q1 results : profit at ₹9.26Cr, Revenue increased by 5.49% YoY
1 min read . 09 Aug 2024Unichem Laboratories Q3 FY24 results: profit at ₹83.99Cr, Revenue increased by 43.6% YoY
1 min read . 07 Feb 2024Q3 results today: Bharti Airtel, Ashok Leyland, 120 others to release Q3 results
1 min read . 05 Feb 2024Unichem Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 1704.89
- Selling/ General/ Admin Expenses Total
- 393.06
- Depreciation/ Amortization
- 113.24
- Other Operating Expenses Total
- 546.96
- Total Operating Expense
- 1778.72
- Operating Income
- -73.83
- Net Income Before Taxes
- -61.67
- Net Income
- -70.47
- Diluted Normalized EPS
- -4.69
- Period
- 2024
- Total Assets
- 3169.34
- Total Liabilities
- 806.93
- Total Equity
- 2362.42
- Tangible Book Valueper Share Common Eq
- 335.32
- Period
- 2024
- Cashfrom Operating Activities
- 16.69
- Cashfrom Investing Activities
- 50.4
- Cashfrom Financing Activities
- -106.31
- Net Changein Cash
- -32.84
- Period
- 2023
- Total Revenue
- 1343.02
- Selling/ General/ Admin Expenses Total
- 711.99
- Depreciation/ Amortization
- 113.44
- Total Operating Expense
- 1535.57
- Operating Income
- -192.54
- Net Income Before Taxes
- -176.36
- Net Income
- -202.23
- Diluted Normalized EPS
- -25.43
- Period
- 2023
- Total Assets
- 3193.05
- Total Liabilities
- 757.74
- Total Equity
- 2435.3
- Tangible Book Valueper Share Common Eq
- 345.68
- Period
- 2023
- Cashfrom Operating Activities
- -48.71
- Cashfrom Investing Activities
- 202.81
- Cashfrom Financing Activities
- -81.3
- Net Changein Cash
- 74.56
- Period
- 2022
- Total Revenue
- 1269.83
- Selling/ General/ Admin Expenses Total
- 670.98
- Depreciation/ Amortization
- 91.17
- Total Operating Expense
- 1283.1
- Operating Income
- -13.27
- Net Income Before Taxes
- 21.97
- Net Income
- 33.06
- Diluted Normalized EPS
- 4.92
- Period
- 2022
- Total Assets
- 3318.77
- Total Liabilities
- 700.36
- Total Equity
- 2618.41
- Tangible Book Valueper Share Common Eq
- 371.68
- Period
- 2022
- Cashfrom Operating Activities
- -259.61
- Cashfrom Investing Activities
- 102.4
- Cashfrom Financing Activities
- 191.23
- Net Changein Cash
- 31.74
- Period
- 2021
- Total Revenue
- 1235.14
- Selling/ General/ Admin Expenses Total
- 673.25
- Depreciation/ Amortization
- 84.36
- Total Operating Expense
- 1227.86
- Operating Income
- 7.28
- Net Income Before Taxes
- 51.48
- Net Income
- 34.32
- Diluted Normalized EPS
- 4.92
- Period
- 2021
- Total Assets
- 3125.71
- Total Liabilities
- 568.88
- Total Equity
- 2556.83
- Tangible Book Valueper Share Common Eq
- 362.94
- Period
- 2021
- Cashfrom Operating Activities
- 40.69
- Cashfrom Investing Activities
- -73.56
- Cashfrom Financing Activities
- -121.19
- Net Changein Cash
- -154.06
- Period
- 2020
- Total Revenue
- 1103.71
- Selling/ General/ Admin Expenses Total
- 670.21
- Depreciation/ Amortization
- 80.89
- Total Operating Expense
- 1234.73
- Operating Income
- -131.02
- Net Income Before Taxes
- -48.21
- Net Income
- -60.18
- Diluted Normalized EPS
- -8.34
- Period
- 2020
- Total Assets
- 3144.74
- Total Liabilities
- 613.38
- Total Equity
- 2531.35
- Tangible Book Valueper Share Common Eq
- 359.32
- Period
- 2020
- Cashfrom Operating Activities
- 132.68
- Cashfrom Investing Activities
- -35.91
- Cashfrom Financing Activities
- -62.3
- Net Changein Cash
- 34.47
- Period
- 2019
- Total Revenue
- 1180.05
- Selling/ General/ Admin Expenses Total
- 705.2
- Depreciation/ Amortization
- 67.37
- Total Operating Expense
- 1321.81
- Operating Income
- -141.77
- Net Income Before Taxes
- -59.91
- Net Income
- -23.8
- Diluted Normalized EPS
- -2.27
- Period
- 2019
- Total Assets
- 3149.61
- Total Liabilities
- 529.7
- Total Equity
- 2619.91
- Tangible Book Valueper Share Common Eq
- 371.98
- Period
- 2019
- Cashfrom Operating Activities
- -327.77
- Cashfrom Investing Activities
- -286.01
- Cashfrom Financing Activities
- -2.42
- Net Changein Cash
- -616.19
- Period
- 2018
- Total Revenue
- 814.98
- Selling/ General/ Admin Expenses Total
- 521.39
- Depreciation/ Amortization
- 50.51
- Total Operating Expense
- 993.15
- Operating Income
- -178.16
- Net Income Before Taxes
- -129.76
- Net Income
- 2544.91
- Diluted Normalized EPS
- -14.37
- Period
- 2018
- Total Assets
- 3193.67
- Total Liabilities
- 513.58
- Total Equity
- 2680.08
- Tangible Book Valueper Share Common Eq
- 380.75
- Period
- 2018
- Cashfrom Operating Activities
- -112.34
- Cashfrom Investing Activities
- 1648.33
- Cashfrom Financing Activities
- -881.13
- Net Changein Cash
- 654.86
- Period
- 2024-06-30
- Total Revenue
- 446.43
- Selling/ General/ Admin Expenses Total
- 98.49
- Depreciation/ Amortization
- 28.33
- Other Operating Expenses Total
- 143.87
- Total Operating Expense
- 431.26
- Operating Income
- 15.17
- Net Income Before Taxes
- 15
- Net Income
- 9.26
- Diluted Normalized EPS
- 1.31
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 431.7
- Selling/ General/ Admin Expenses Total
- 99.42
- Depreciation/ Amortization
- 27.16
- Other Operating Expenses Total
- 140.04
- Total Operating Expense
- 559.13
- Operating Income
- -127.43
- Net Income Before Taxes
- -125.87
- Net Income
- -129.31
- Diluted Normalized EPS
- -6.77
- Period
- 2024-03-31
- Total Assets
- 3169.34
- Total Liabilities
- 806.93
- Total Equity
- 2362.42
- Tangible Book Valueper Share Common Eq
- 335.32
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 16.69
- Cashfrom Investing Activities
- 50.4
- Cashfrom Financing Activities
- -106.31
- Net Changein Cash
- -32.84
- Period
- 2023-12-31
- Total Revenue
- 434.38
- Selling/ General/ Admin Expenses Total
- 98.11
- Depreciation/ Amortization
- 27.86
- Other Operating Expenses Total
- 131.66
- Total Operating Expense
- 359.33
- Operating Income
- 75.05
- Net Income Before Taxes
- 83.97
- Net Income
- 83.99
- Diluted Normalized EPS
- 5.65
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 415.63
- Selling/ General/ Admin Expenses Total
- 96.72
- Depreciation/ Amortization
- 29.45
- Other Operating Expenses Total
- 147.34
- Total Operating Expense
- 436.32
- Operating Income
- -20.69
- Net Income Before Taxes
- -21.88
- Net Income
- -24.49
- Diluted Normalized EPS
- -3.48
- Period
- 2023-09-30
- Total Assets
- 3069.93
- Total Liabilities
- 661.92
- Total Equity
- 2408.01
- Tangible Book Valueper Share Common Eq
- 341.8
- Period
- 2023-09-30
- Cashfrom Operating Activities
- -77.58
- Cashfrom Investing Activities
- -8.79
- Cashfrom Financing Activities
- -36.67
- Net Changein Cash
- -120.61
- Period
- 2023-06-30
- Total Revenue
- 423.19
- Selling/ General/ Admin Expenses Total
- 98.81
- Depreciation/ Amortization
- 28.77
- Other Operating Expenses Total
- 127.92
- Total Operating Expense
- 423.94
- Operating Income
- -0.75
- Net Income Before Taxes
- 2.12
- Net Income
- -0.67
- Diluted Normalized EPS
- -0.09
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 402.1
- Selling/ General/ Admin Expenses Total
- 88.73
- Depreciation/ Amortization
- 29.68
- Other Operating Expenses Total
- 121.84
- Total Operating Expense
- 448.84
- Operating Income
- -46.74
- Net Income Before Taxes
- -47.16
- Net Income
- -44.27
- Diluted Normalized EPS
- -3.03
- Period
- 2023-03-31
- Total Assets
- 3193.05
- Total Liabilities
- 757.74
- Total Equity
- 2435.3
- Tangible Book Valueper Share Common Eq
- 345.68
- Period
- 2023-03-31
- Cashfrom Operating Activities
- -48.71
- Cashfrom Investing Activities
- 202.81
- Cashfrom Financing Activities
- -81.3
- Net Changein Cash
- 74.56
- Period
- 2022-12-31
- Total Revenue
- 302.5
- Selling/ General/ Admin Expenses Total
- 90.57
- Depreciation/ Amortization
- 30.78
- Other Operating Expenses Total
- 116.3
- Total Operating Expense
- 376.04
- Operating Income
- -73.54
- Net Income Before Taxes
- -61.28
- Net Income
- -63.93
- Diluted Normalized EPS
- -9.03
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Unichem Laboratories Technical
Moving Average
SMA
- 5 Day699.8
- 10 Day674.03
- 20 Day661.59
- 50 Day611.68
- 100 Day575.46
- 300 Day540.95
Unichem Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Neuland Laboratories
- 15352.15
- -956.4
- -5.86
- 16501
- 3612.05
- 19696.64
- Astrazeneca Pharma India
- 7623.15
- -8.25
- -0.11
- 8139.85
- 4050.15
- 19057.88
- Unichem Laboratories
- 725.9
- -2.6
- -0.36
- 755.15
- 398.7
- 5110.75
- Themis Medicare
- 269.1
- -5.75
- -2.09
- 304.3
- 142.6
- 2476.8
- Jagsonpal Pharmaceuticals
- 474.25
- 24.65
- 5.48
- 496.2
- 270.05
- 1253.81
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Neuland Laboratories
- 63.05
- 15.65
- 14.98
- 11.99
- Astrazeneca Pharma India
- 126.67
- 26.74
- 20.1
- 10.27
- Unichem Laboratories
- -
- 2.22
- -2.1
- -3.99
- Themis Medicare
- 58.78
- 6.76
- 18.03
- 14.96
- Jagsonpal Pharmaceuticals
- 52.28
- 6.41
- 13.79
- 9.21
Unichem Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 30-Sept-24
- Others
- 08-Aug-24
- Quarterly Results
- 22-May-24
- Audited Results
- 05-Feb-24
- Quarterly Results
- 01-Nov-23
- Quarterly Results
- 14-Jul-23
- Quarterly Results
- 23-May-23
- Audited Results
- 06-Feb-23
- Quarterly Results
- 11-Nov-22
- Quarterly Results
- 09-Aug-22
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 24-Mar-24
- 21-Feb-24
- POM
- 25-Sept-23
- 09-Aug-23
- AGM
- 05-May-23
- 03-Apr-23
- POM
- 09-Aug-22
- 28-Jun-22
- AGM
- 31-Jul-21
- 22-Jun-21
- AGM
- 29-May-21
- 27-Apr-21
- POM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 27-May-22
- -
- 01-Aug-22
- 4
- 31-May-21
- -
- 22-Jul-21
- 4